Skip to main content
Clinical Trials/NCT01948999
NCT01948999
Terminated
Not Applicable

Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study

University of Aarhus0 sites3 target enrollmentDecember 2013

Overview

Phase
Not Applicable
Intervention
ECT
Conditions
Treatment-refractory Schizophrenia
Sponsor
University of Aarhus
Enrollment
3
Primary Endpoint
Reduction in total PANSS score and adverse events
Status
Terminated
Last Updated
9 years ago

Overview

Brief Summary

The purpose of the study is to determine whether addition of electroconvulsive therapy to antipsychotic treatment improves the mental health of patients with treatment-resistant schizophrenia.

Detailed Description

The purpose of the study is not achieved.

Registry
clinicaltrials.gov
Start Date
December 2013
End Date
December 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • An ICD-10 schizophrenia diagnosis F20.0-20.3 or F20.9
  • PANSS total score \>= 70
  • CGI-S \>= 4 (Clinical Global Impression)
  • PANSS score \>= 4 on minimum 2 og the following items: Delusions, Conceptual disorganization,Hallucinatory behavior, Excitement, Grandiosity, Suspiciousness, Hostility, Disorientation.
  • Previous/current treated with clozapine or refused clozapine treatment
  • Lack of response to at least three different antipsychotics
  • New antipsychotic medication prescribed more than 8 weeks before inclusion
  • Fixed dosage of antipsychotics 1 month before inclusion
  • No chance of additional neurotropic 4 weeks before inclusion
  • Signed informed consent and power of attorney

Exclusion Criteria

  • Significant substance abuse
  • Somatic disease that increases the risk of complications of ECT/anesthesia
  • For women: Pregnancy or breast-feeding
  • Homelessness
  • Use of benzodiazepines (apart from tbl. oxazepam 10 mg., max 30 mg. daily)
  • Use of antiepileptic
  • Previous no effect on psychotic symptoms after ECT treatment (minimum 15 ECT- treatments)
  • Concrete suicidal plans

Arms & Interventions

ECT

Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis

Intervention: ECT

ECT

Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis

Intervention: Anesthesia

SHAM ECT

Anesthesia and concomitant muscular paralysis

Intervention: SHAM ECT

SHAM ECT

Anesthesia and concomitant muscular paralysis

Intervention: Anesthesia

Outcomes

Primary Outcomes

Reduction in total PANSS score and adverse events

Time Frame: The primary outcome will be assessed at screening, baseline and after every second week up to 72 weeks depending on the process for the individaul participant.

PANSS = Positive and Negative Syndrome Scale and UKU = The UKU (Udvalg for Kliniske Undersøgelser) side effect rating scale

Similar Trials